Startseite Kongressberichte & Archiv 23rd Congress of EHA Important Multiple Myeloma Presentations Advances in front-line treatment of newly diagnosed multiple myeloma

Advances in front-line treatment of newly diagnosed multiple myeloma

(S105) A TRIPLET BORTEZOMIB- AND IMMUNOMODULATOR-BASED THERAPY BEFORE AND AFTER DOUBLE ASCT IMPROVES OVERALL SURVIVAL OF NEWLY DIAGNOSED MM PATIENTS: FINAL ANALYSIS OF PHASE 3 GIMEMA-MMY-3006 STUDY

Paola Tacchetti, et al. ABSTRACT

Conclusion
With an extended median follow-up of 7.6 years,  a persistent PFS benefit with incorporation of VTD into ASCT was confirmed. Moreover, a longer OS from primary randomization to VTD versus TD was demonstrated in the overall population, as well as in subgroups of patients with high risk and low risk MM.

 

(S106) AUTOLOGOUS STEM CELL TRANSPLANTATION IS SAFE AND EFFECTIVE FOR OLDER MYELOMA PATIENTS: RESULTS FROM THE MYELOMA XI TRIAL

Charlotte Pawlyn, et al. ABSTRACT

Conclusion

Our data suggests that ASCT improves outcomes for newly diagnosed myeloma patients and supports its use as standard of care for all considered able to tolerate the procedure, without strict age limits.

 

(S107) DARATUMUMAB PLUS BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) IN ELDERLY (≥75 YEARS OF AGE) PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA INELIGIBLE FOR TRANSPLANTATION (ALCYONE)

Jesus San-Miguel, et al. ABSTRACT

Conclusion
The efficacy of D-VMP vs VMP in patients ≥75 years of age was consistent with the overall study population. Furthermore, D in combination with VMP demonstrated acceptable tolerability regardless of age.

 

(S108) CONSOLIDATION FOLLOWED BY MAINTENANCE VS MAINTENANCE ALONE IN NEWLY DIAGNOSED, TRANSPLANT ELIGIBLE MULTIPLE MYELOMA: A RANDOMIZED PHASE 3 STUDY OF THE EUROPEAN MYELOMA NETWORK (EMN02/HO95 MM TRIAL)

P Sonneveld, et al. ABSTRACT

Conclusion
This second interim analysis confirms the initial promising results of consolidation treatment with VRD followed by lenalidomide maintenance until progression or toxicity as compared to maintenance alone for younger NDMM patients, but further study follow-up is needed. This trial was supported by the Dutch Cancer Society (grant 2010-4798) and by unrestricted grants from Celgene and Janssen. 

 

(S109) UPDATED EFFICACY AND MRD DATA ACCORDING TO RISK-STATUS IN NEWLY DIAGNOSED MYELOMA PATIENTS TREATED WITH CARFILZOMIB PLUS LENALIDOMIDE OR CYCLOPHOSPHAMIDE: RESULTS FROM THE FORTE TRIAL

Francesca Gay, et al. ABSTRACT

Conclusion
K-based induction in transplant-eligible patients is well tolerated and induces deep responses. KRd induction significantly improved sCR/CR, ≥nCR and ≥VGPR vs KCd. Rate of MRD negativity on evaluable patients was also higher with KRd. The regimen was similarly effective in high-risk patients, currently representing an unmet medical need.